ECEric Crouch

Eric Crouch

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Eric Crouch has a total of 31 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    External Validation of Deep Learning Models for Classifying Etiology of Retinal Hemorrhage Using Diverse Fundus Photography Datasets

    by Pooya Khosravi, Nolan A. Huck, Kourosh Shahraki, Elina Ghafari, Reza Azimi, So Young Kim, Eric Crouch, Xiaohui Xie, Donny W. Suh

    Retinal hemorrhage (RH) is a significant clinical finding with various etiologies, necessitating accurate classification for effective management. This study aims to externally validate deep learning (DL) models, specifically FastVit_SA12 and ResNet18, for distinguishing between traumatic and medical causes of RH using diverse fundus photography datasets. A comprehensive dataset was compiled, including private collections from South Korea and Virginia, alongside publicly available datasets such as RFMiD, BRSET, and DeepEyeNet. The models were evaluated on a total of 2661 images, achieving high performance metrics. FastVit_SA12 demonstrated an overall accuracy of 96.99%, with a precision of 0.9935 and recall of 0.9723 for medical cases, while ResNet18 achieved a 94.66% accuracy with a precision of 0.9893. A Grad-CAM analysis revealed that ResNet18 emphasized global vascular patterns, such as arcuate vessels, while FastVit_SA12 focused on clinically relevant areas, including the optic disk and hemorrhagic regions. Medical cases showed localized activations, whereas trauma-related images displayed diffuse patterns across the fundus. Both models exhibited strong sensitivity and specificity, indicating their potential utility in clinical settings for accurate RH diagnosis. This study underscores the importance of external validation in enhancing the reliability and applicability of AI models in ophthalmology, paving the way for improved patient care and outcomes.


  • A prospective study of treatments for adult-onset divergence insufficiency–type esotropia

    by Eric R. Crouch, Trevano W. Dean, Raymond T. Kraker, Aaron M. Miller, Courtney L. Kraus, Kammi B. Gunton, Michael X. Repka, Justin D. Marsh, Monte A. Del Monte, Paula A. Luke, et al.


  • Open Access

    Partial uniparental isodisomy of chromosome 16 unmasks a deleterious biallelic mutation in IFT140 that causes Mainzer-Saldino syndrome

    by Benjamin M. Helm, Jason R. Willer, Azita Sadeghpour, Christelle Golzio, Eric Crouch, Samantha Schrier Vergano, Nicholas Katsanis, Erica E. Davis

    The ciliopathies represent an umbrella group of >50 clinical entities that share both clinical features and molecular etiology underscored by structural and functional defects of the primary cilium. Despite the advances in gene discovery, this group of entities continues to pose a diagnostic challenge, in part due to significant genetic and phenotypic heterogeneity and variability. We consulted a pediatric case from asymptomatic, non-consanguineous parents who presented as a suspected ciliopathy due to a constellation of retinal, renal, and skeletal findings. Although clinical panel sequencing of genes implicated in nephrotic syndromes yielded no likely causal mutation, an oligo-SNP microarray identified a ~20-Mb region of homozygosity, with no altered gene dosage, on chromosome 16p13. Intersection of the proband’s phenotypes with known disease genes within the homozygous region yielded a single candidate, IFT140, encoding a retrograde intraflagellar transport protein implicated previously in several ciliopathies, including the phenotypically overlapping Mainzer-Saldino syndrome (MZSDS). Sanger sequencing yielded a maternally inherited homozygous c.634G>A; p.Gly212Arg mutation altering the exon 6 splice donor site. Functional studies in cells from the proband showed that the locus produced two transcripts: a majority message containing a mis-splicing event that caused a premature termination codon and a minority message homozygous for the p.Gly212Arg allele. Zebrafish in vivo complementation studies of the latter transcript demonstrated a loss of function effect. Finally, we conducted post-hoc trio-based whole exome sequencing studies to (a) test the possibility of other causal loci in the proband and (b) explain the Mendelian error of segregation for the IFT140 mutation. We show that the proband harbors a chromosome 16 maternal heterodisomy, with segmental isodisomy at 16p13, likely due to a meiosis I error in the maternal gamete. Using clinical phenotyping combined with research-based genetic and functional studies, we have characterized a recurrent IFT140 mutation in the proband; together, these data are consistent with MZSDS. Additionally, we report a rare instance of a uniparental isodisomy unmasking a deleterious mutation to cause a ciliary disorder.


  • Use of botulinum toxin in strabismus

    by Eric R Crouch

    The history, pharmacology, indications, complications, and success rates of botulinum administration are discussed in this review as they relate to strabismus and associated conditions. Botulinum has been used to treat strabismus and a variety of other ocular conditions for over three decades. Alan Scott initially investigated extraocular muscle paralysis by botulinum injection in 1973, and in the ensuing years botulinum has been evaluated as a treatment for horizontal and vertical strabismus, nystagmus, dissociated vertical deviation, sensory strabismus, ophthalmoplegia, and paradoxical diplopia. Botulinum administration is a strabismus treatment option that may be considered for some strabismus patients; in select cases botulinum is a reasonable and preferable alternative to surgery. Current clinical recommendations regarding botulinum should be considered in the context of the existing comparative studies that are summarized in this review. Since there are very limited data directly comparing the success rates of botulinum with standard strabismus surgery, additional, well designed prospective studies are needed. Data from such studies would enable recommendations for strabismus management to be formulated using an evidence-based approach.